Kotak Institutional Equities has struck a bullish note on Piramal Pharma with its latest research, reiterating a BUY recommendation and projecting a fair value of Rs305 per share against a current
Motilal Oswal has issued a BUY call on Piramal Pharma with a revised target price of Rs 310, indicating a 21% upside from its current market price of Rs 256.